| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ana Muñoz, Qin Li, Fabrizio Gardoni, Elena Marcello, Chuan Qin, Thomas Carlsson, Deniz Kirik, Monica Di Luca, Anders Björklund, Erwan Bezard, Manolo Cart. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain : a journal of neurology. vol 131. issue Pt 12. 2009-02-02. PMID:18952677. |
we have recently demonstrated that dopamine released from serotonin neurons is responsible for l-dopa-induced dyskinesia in 6-hydroxydopamine (6-ohda)-lesioned rats, raising the possibility that blockade of serotonin neuron activity by combination of 5-ht(1a) and 5-ht(1b) agonists could reduce l-dopa-induced dyskinesia. |
2009-02-02 |
2023-08-12 |
rat |
| A Vinuela, P J Hallett, C Reske-Nielsen, M Patterson, T D Sotnikova, M G Caron, R R Gainetdinov, O Isacso. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain : a journal of neurology. vol 131. issue Pt 12. 2009-02-02. PMID:18988638. |
to address this issue we transplanted foetal dopaminergic neurons from mice lacking the dopamine transporter (datko) or from wild-type mice, into a rat model of parkinson's disease and l-dopa-induced dyskinesias. |
2009-02-02 |
2023-08-12 |
mouse |
| Manolo Carta, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklun. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progress in brain research. vol 172. 2009-01-15. PMID:18772046. |
an increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of l-dopa-induced dyskinesia. |
2009-01-15 |
2023-08-12 |
human |
| Manolo Carta, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklun. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism & related disorders. vol 14 Suppl 2. 2008-12-12. PMID:18579429. |
indeed, an increasing body of evidence points to dopamine released as a false neurotransmitter from the serotonin terminals as the main pre-synaptic determinant of l-dopa-induced dyskinesias in animal models of parkinson's disease. |
2008-12-12 |
2023-08-12 |
Not clear |
| Heinz Reichman. Initiation of Parkinson's disease treatment. Journal of neurology. vol 255 Suppl 5. 2008-12-12. PMID:18787883. |
in my opinion, initial treatment with a mao-b-inhibitor and subsequent combination with a long-acting dopamine agonist may be even more promising with regard to neuroprotection, modification of the disease, avoidance of dyskinesia and good motor improvement. |
2008-12-12 |
2023-08-12 |
Not clear |
| Takahiro Iizuka, Fumihiko Saka. [Anti-nMDA receptor encephalitis--clinical manifestations and pathophysiology]. Brain and nerve = Shinkei kenkyu no shinpo. vol 60. issue 9. 2008-11-18. PMID:18807939. |
this results in disinhibition of postsynaptic glutamatergic transmission, excessive release of glutamate in the prefrontal/subcortical structures, and glutamate and dopamine dysregulation that might contribute to development of schizophrenia-like psychosis and bizarre dyskinesias. |
2008-11-18 |
2023-08-12 |
Not clear |
| J C Möller, K M Eggert, M Unger, P Odin, K R Chaudhuri, W H Oerte. Clinical risk-benefit assessment of dopamine agonists. European journal of neurology. vol 15 Suppl 2. 2008-10-28. PMID:18702738. |
dopamine agonists (das) have proven efficacy as monotherapy in early parkinson's disease (pd) for preventing motor complications such as dyskinesia and as adjunct therapy as the disease progresses. |
2008-10-28 |
2023-08-12 |
Not clear |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 6. 2008-10-22. PMID:18554768. |
differential striatal levels of tnf-alpha, nfkappab p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. |
2008-10-22 |
2023-08-12 |
human |
| Anna R Carta, Lucia Frau, Frau Lucia, Annalisa Pinna, Pinna Annalisa, Silvia Pontis, Pontis Silvia, Nicola Simola, Simola Nicola, Nicoletta Schintu, Schintu Nicoletta, Micaela Morelli, Morelli Micael. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (New York, N.Y.). vol 62. issue 7. 2008-08-11. PMID:18435422. |
the present study was aimed at assessing behavioral and biochemical correlates of intense or mild dyskinesia displayed by the different dopamine (da) receptors stimulation in a rat model of pd. |
2008-08-11 |
2023-08-12 |
rat |
| K A Stockwell, D J Virley, M Perren, M M Iravani, M J Jackson, S Rose, P Jenne. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Experimental neurology. vol 211. issue 1. 2008-07-30. PMID:18321484. |
however, standard oral administration of dopamine agonists does not result in constant plasma drug levels, therefore, more continuous drug delivery may result in both prolonged reversal of motor deficits and reduced levels of dyskinesia. |
2008-07-30 |
2023-08-12 |
Not clear |
| A Antonini, F Mancini, M Canesi, R Zangaglia, I U Isaias, L Manfredi, C Pacchetti, M Zibetti, F Natuzzi, L Lopiano, G Nappi, G Pezzol. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neuro-degenerative diseases. vol 5. issue 3-4. 2008-05-15. PMID:18322402. |
a significant percentage of patients with parkinson's disease (pd) continue to experience motor fluctuations and dyskinesias despite the association of dopamine agonists and levodopa with comt or mao-b inhibitors. |
2008-05-15 |
2023-08-12 |
Not clear |
| Mark Stacy, Andrew Galbreat. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clinical neuropharmacology. vol 31. issue 1. 2008-03-11. PMID:18303491. |
optimizing long-term therapy for parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. |
2008-03-11 |
2023-08-12 |
Not clear |
| Virgili Pérez, Victoria Sosti, Antonia Rubio, Manel Barbanoj, José Rodríguez-Alvarez, Jaime Kulisevsk. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. European journal of pharmacology. vol 576. issue 1-3. 2008-03-06. PMID:17888901. |
locus coeruleus degeneration might influence the response to dopamine replacement and the presence of long-term complications such as dyskinesias. |
2008-03-06 |
2023-08-12 |
rat |
| Stephen J Gold, Chau V Hoang, Bryan W Potts, Gregory Porras, Elsa Pioli, Ki Woo Kim, Agnes Nadjar, Chuan Qin, Gerald J LaHoste, Qin Li, Bernard H Bioulac, Jeffrey L Waugh, Eugenia Gurevich, Rachael L Neve, Erwan Bezar. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 52. 2008-02-05. PMID:18160641. |
chronic l-dopa treatment of parkinson's disease (pd) often leads to debilitating involuntary movements, termed l-dopa-induced dyskinesia (lid), mediated by dopamine (da) receptors. |
2008-02-05 |
2023-08-12 |
mouse |
| Mohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, Kim A Stockwell, Lance A Smith, Sarah Rose, Warren Olanow, Peter Jenne. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental neurology. vol 208. issue 2. 2008-01-31. PMID:17935716. |
the administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in mptp-treated primates. |
2008-01-31 |
2023-08-12 |
Not clear |
| Mohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, Kim A Stockwell, Lance A Smith, Sarah Rose, Warren Olanow, Peter Jenne. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental neurology. vol 208. issue 2. 2008-01-31. PMID:17935716. |
we now investigate whether l-dopa delivery also influences dyskinesia induction when added to dopamine agonist treatment. |
2008-01-31 |
2023-08-12 |
Not clear |
| Mohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, Kim A Stockwell, Lance A Smith, Sarah Rose, Warren Olanow, Peter Jenne. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental neurology. vol 208. issue 2. 2008-01-31. PMID:17935716. |
the results show that combined treatment with l-dopa and entacapone has a marked effect on dyskinesia induction even when therapy has been introduced with a dopamine agonist. |
2008-01-31 |
2023-08-12 |
Not clear |
| Roselei Fachinetto, Jardel G Villarinho, Caroline Wagner, Romaiana P Pereira, Daiana Silva Avila, Marilise E Burger, João Batista Calixto, João B T Rocha, Juliano Ferreir. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 7. 2007-12-06. PMID:17669571. |
valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. |
2007-12-06 |
2023-08-12 |
rat |
| Francesco Fornai, Adolfo Bandettini di Poggio, Antonio Pellegrini, Stefano Ruggieri, Antonio Paparell. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Current medicinal chemistry. vol 14. issue 22. 2007-12-03. PMID:17896981. |
novel data also show that the loss of noradrenergic innervation facilitates the onset of dyskinesia occurring in parkinsonian patients during dopamine replacement therapy. |
2007-12-03 |
2023-08-12 |
Not clear |
| Marina Delfino, Raffael Kalisch, Michael Czisch, Celia Larramendy, Jimena Ricatti, Irene R E Taravini, Claudia Trenkwalder, Mario Gustavo Murer, Dorothee P Auer, Oscar S Gershani. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 9. 2007-11-29. PMID:17287822. |
the mechanisms underlying dopamine agonist-induced dyskinesia in parkinson's disease remain poorly understood. |
2007-11-29 |
2023-08-12 |
rat |